Collegium Pharmaceutical, Inc. Net Income
Collegium Pharmaceutical, Inc. (COLL) reported Net Income of -$15.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$15.05M, a 225.60% decline year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $14.50M, a 499.75% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $16.96M, a 35.31% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $31.51M, a 237.51% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for fiscal 2020 was $26.75M.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for fiscal 2019 was -$22.72M.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for fiscal 2018 was -$39.13M.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent for fiscal 2017 was -$74.86M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$15.05M 10-Q · filed 2026-08-06 | -$555.00K 10-Q · filed 2026-08-06 | $16.41M derived: sum of 3 quarters · filed 2026-08-06 | $47.91M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $14.50M 10-Q · filed 2026-08-06 | $31.46M derived: sum of 2 quarters · filed 2026-08-06 | $62.97M derived: sum of 3 quarters · filed 2026-08-06 | $74.95M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $16.96M 10-K · filed 2026-02-26 | $48.47M derived: sum of 2 quarters · filed 2026-02-26 | $60.45M derived: sum of 3 quarters · filed 2026-08-06 | $63.00M DEF 14A · filed 2026-04-07 | $62.87M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $31.51M 10-K · filed 2026-02-26 | $43.49M derived: sum of 2 quarters · filed 2026-08-06 | $45.91M 10-Q · filed 2025-11-06 | $58.44M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $11.98M 10-Q · filed 2026-08-06 | $14.40M 10-Q · filed 2026-08-06 | $26.94M derived: sum of 3 quarters · filed 2026-08-06 | $36.27M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.42M 10-Q · filed 2026-08-06 | $14.95M derived: sum of 2 quarters · filed 2026-08-06 | $24.29M derived: sum of 3 quarters · filed 2026-08-06 | $43.89M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2024-12-31 | $12.54M 10-K · filed 2026-02-26 | $21.87M derived: sum of 2 quarters · filed 2026-02-26 | $41.48M derived: sum of 3 quarters · filed 2026-02-26 | $69.00M DEF 14A · filed 2026-04-07 | $69.19M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $9.34M 10-K · filed 2026-02-26 | $28.94M derived: sum of 2 quarters · filed 2026-02-26 | $56.65M 10-Q · filed 2025-11-06 | $88.59M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $19.61M 10-K · filed 2026-02-26 | $47.32M 10-Q · filed 2025-08-07 | $79.26M derived: sum of 3 quarters · filed 2026-02-26 | $99.89M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $27.71M 10-K · filed 2026-02-26 | $59.65M derived: sum of 2 quarters · filed 2026-02-26 | $80.29M derived: sum of 3 quarters · filed 2026-02-26 | $93.29M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $31.94M 10-K · filed 2025-02-27 | $52.57M derived: sum of 2 quarters · filed 2025-02-27 | $65.58M derived: sum of 3 quarters · filed 2025-02-27 | $48.00M DEF 14A · filed 2026-04-07 | $48.16M 10-K · filed 2024-02-22 | |
| 2023-09-30 | $20.63M 10-K · filed 2025-02-27 | $33.64M derived: sum of 2 quarters · filed 2025-02-27 | $16.21M 10-Q · filed 2024-11-07 | $9.02M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $13.01M 10-K · filed 2025-02-27 | -$4.42M 10-Q · filed 2024-08-08 | -$11.62M derived: sum of 3 quarters · filed 2025-02-27 | -$11.16M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$17.43M 10-K · filed 2025-02-27 | -$24.63M derived: sum of 2 quarters · filed 2025-02-27 | -$24.17M derived: sum of 3 quarters · filed 2025-02-27 | -$29.36M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$7.20M 10-K · filed 2024-02-22 | -$6.74M derived: sum of 2 quarters · filed 2024-02-22 | -$11.93M derived: sum of 3 quarters · filed 2024-02-22 | -$25.00M DEF 14A · filed 2026-04-07 | -$25.00M 10-K · filed 2023-02-23 | |
| 2022-09-30 | $457.00K 10-K · filed 2024-02-22 | -$4.73M derived: sum of 2 quarters · filed 2024-02-22 | -$17.80M 10-Q · filed 2023-11-07 | -$42.84M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | -$5.19M 10-K · filed 2024-02-22 | -$18.26M 10-Q · filed 2023-08-03 | -$43.29M derived: sum of 3 quarters · filed 2024-02-22 | -$35.25M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | -$13.07M 10-K · filed 2024-02-22 | -$38.10M derived: sum of 2 quarters · filed 2024-02-22 | -$30.06M derived: sum of 3 quarters · filed 2024-02-22 | $42.79M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | -$25.03M 10-K · filed 2023-02-23 | -$16.99M derived: sum of 2 quarters · filed 2023-02-23 | $55.85M derived: sum of 3 quarters · filed 2023-02-23 | $72.00M DEF 14A · filed 2026-04-07 | $71.52M 10-K · filed 2022-02-24 | |
| 2021-09-30 | $8.05M 10-K · filed 2023-02-23 | $80.89M derived: sum of 2 quarters · filed 2023-02-23 | $96.55M 10-Q · filed 2022-11-03 | $103.51M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $72.84M 10-K · filed 2023-02-23 | $88.50M 10-Q · filed 2022-08-04 | $95.46M derived: sum of 3 quarters · filed 2023-02-23 | $106.75M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $15.66M 10-K · filed 2023-02-23 | $22.62M derived: sum of 2 quarters · filed 2023-02-23 | $33.91M derived: sum of 3 quarters · filed 2023-02-23 | $41.96M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $6.96M 10-K · filed 2022-02-24 | $18.24M derived: sum of 2 quarters · filed 2022-02-24 | $26.30M derived: sum of 3 quarters · filed 2022-02-24 | $26.75M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $11.29M 10-K · filed 2022-02-24 | $19.34M derived: sum of 2 quarters · filed 2022-02-24 | $19.79M 10-Q · filed 2021-11-04 | $17.59M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $8.06M 10-K · filed 2022-02-24 | $8.51M 10-Q · filed 2021-08-05 | $6.31M derived: sum of 3 quarters · filed 2022-02-24 | $198.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $450.00K 10-K · filed 2022-02-24 | -$1.75M derived: sum of 2 quarters · filed 2022-02-24 | -$7.86M derived: sum of 3 quarters · filed 2022-02-24 | -$12.57M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$2.20M 10-K · filed 2021-02-25 | -$8.31M derived: sum of 2 quarters · filed 2021-02-25 | -$13.02M derived: sum of 3 quarters · filed 2021-02-25 | -$22.72M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$6.11M 10-K · filed 2021-02-25 | -$10.82M derived: sum of 2 quarters · filed 2021-02-25 | -$20.52M 10-Q · filed 2020-11-05 | -$11.44M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | -$4.71M 10-K · filed 2021-02-25 | -$14.41M 10-Q · filed 2020-08-05 | -$5.33M derived: sum of 3 quarters · filed 2021-02-25 | -$21.83M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | -$9.70M 10-K · filed 2021-02-25 | -$614.00K derived: sum of 2 quarters · filed 2021-02-25 | -$17.12M derived: sum of 3 quarters · filed 2021-02-25 | -$30.18M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $9.09M 10-K · filed 2020-02-27 | -$7.42M derived: sum of 2 quarters · filed 2020-02-27 | -$20.48M derived: sum of 3 quarters · filed 2020-02-27 | -$39.13M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$16.50M 10-K · filed 2020-02-27 | -$29.56M derived: sum of 2 quarters · filed 2020-02-27 | -$48.21M 10-Q · filed 2019-11-06 | -$65.62M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-06-30 | -$13.06M 10-K · filed 2020-02-27 | -$31.71M 10-Q · filed 2019-08-07 | -$49.12M derived: sum of 3 quarters · filed 2020-02-27 | -$62.38M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-03-31 | -$18.65M 10-K · filed 2020-02-27 | -$36.05M derived: sum of 2 quarters · filed 2020-02-27 | -$49.32M derived: sum of 3 quarters · filed 2020-02-27 | -$70.44M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2017-12-31 | -$17.40M 10-K · filed 2019-02-27 | -$30.67M derived: sum of 2 quarters · filed 2019-02-27 | -$51.79M derived: sum of 3 quarters · filed 2019-02-27 | -$74.86M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | -$13.26M 10-K · filed 2019-02-27 | -$34.38M derived: sum of 2 quarters · filed 2019-02-27 | -$57.46M 10-Q · filed 2018-11-08 | -$85.02M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | -$21.12M 10-K · filed 2019-02-27 | -$44.20M 10-Q · filed 2018-08-08 | -$71.76M derived: sum of 3 quarters · filed 2019-02-27 | -$98.20M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | -$23.08M 10-K · filed 2019-02-27 | -$50.64M derived: sum of 2 quarters · filed 2019-02-27 | -$77.08M derived: sum of 3 quarters · filed 2019-02-27 | -$101.60M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | -$27.56M 10-K · filed 2018-03-07 | -$54.00M derived: sum of 2 quarters · filed 2018-03-07 | -$78.52M derived: sum of 3 quarters · filed 2018-03-07 | -$94.18M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | -$26.44M 10-K · filed 2018-03-07 | -$50.96M derived: sum of 2 quarters · filed 2018-03-07 | -$66.62M 10-Q · filed 2017-11-08 | -$76.14M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2016-06-30 | -$24.52M 10-K · filed 2018-03-07 | -$40.17M 10-Q · filed 2017-08-09 | -$49.70M derived: sum of 3 quarters · filed 2018-03-07 | -$59.06M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2016-03-31 | -$15.65M 10-K · filed 2018-03-07 | -$25.18M derived: sum of 2 quarters · filed 2018-03-07 | -$34.54M derived: sum of 3 quarters · filed 2018-03-07 | -$39.21M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2015-12-31 | -$9.53M 10-K · filed 2017-03-10 | -$18.89M derived: sum of 2 quarters · filed 2017-03-10 | -$23.56M derived: sum of 3 quarters · filed 2017-03-10 | -$27.25M 10-K · filed 2018-03-07 | ||
| 2015-09-30 | -$9.36M 10-K · filed 2017-03-10 | -$14.04M derived: sum of 2 quarters · filed 2017-03-10 | -$17.73M 10-Q · filed 2016-11-10 | -$21.20M derived: sum of 4 quarters · filed 2017-03-10 | ||
| 2015-06-30 | -$4.67M 10-K · filed 2017-03-10 | -$8.37M 10-Q · filed 2016-08-11 | -$11.84M derived: sum of 3 quarters · filed 2017-03-10 | -$18.39M derived: sum of 4 quarters · filed 2017-03-10 | ||
| 2015-03-31 | -$3.69M 10-K · filed 2017-03-10 | -$7.16M derived: sum of 2 quarters · filed 2017-03-10 | -$13.72M derived: sum of 3 quarters · filed 2017-03-10 | -$17.84M derived: sum of 4 quarters · filed 2017-03-10 | ||
| 2014-12-31 | -$3.47M 10-K · filed 2016-03-18 | -$10.03M derived: sum of 2 quarters · filed 2016-03-18 | -$14.14M derived: sum of 3 quarters · filed 2016-03-18 | -$17.92M 10-K · filed 2017-03-10 | ||
| 2014-09-30 | -$6.56M 10-K · filed 2016-03-18 | -$10.67M derived: sum of 2 quarters · filed 2016-03-18 | -$14.45M 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | -$4.12M 10-K · filed 2016-03-18 | -$7.89M 10-Q · filed 2015-08-12 | ||||
| 2014-03-31 | -$3.77M 10-K · filed 2016-03-18 | -$3.77M 10-Q/A · filed 2015-07-17 | ||||
| 2013-12-31 | -$16.20M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |